351 related articles for article (PubMed ID: 19035889)
1. Risk-adapted use of intravesical chemotherapy.
Lerner SP; Au JL
BJU Int; 2008 Nov; 102(9 Pt B):1247-53. PubMed ID: 19035889
[No Abstract] [Full Text] [Related]
2. Intravesical chemotherapy.
Prout GR
Prog Clin Biol Res; 1984; 162B():125-50. PubMed ID: 6438639
[No Abstract] [Full Text] [Related]
3. Impact of intravesical chemotherapy versus BCG immunotherapy on recurrence of superficial transitional cell carcinoma of the bladder: metaanalytic reevaluation.
Huncharek M; Kupelnick B
Am J Clin Oncol; 2003 Aug; 26(4):402-7. PubMed ID: 12902895
[TBL] [Abstract][Full Text] [Related]
4. Risk-adapted use of intravesical immunotherapy.
Braasch MR; Böhle A; O'Donnell MA
BJU Int; 2008 Nov; 102(9 Pt B):1254-64. PubMed ID: 19035890
[No Abstract] [Full Text] [Related]
5. Editorial comment on: Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with Bacillus Calmette-Guérin (BCG) in patients with non-muscle-invasive bladder cancer.
Evans CP
Eur Urol; 2007 Oct; 52(4):1129-30. PubMed ID: 17383082
[No Abstract] [Full Text] [Related]
6. Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with Bacillus Calmette-Guérin (BCG) in patients with non-muscle-invasive bladder carcinoma.
Friedrich MG; Pichlmeier U; Schwaibold H; Conrad S; Huland H
Eur Urol; 2007 Oct; 52(4):1123-29. PubMed ID: 17383080
[TBL] [Abstract][Full Text] [Related]
7. Point. Routine use of postoperative intravesical chemotherapy after TURBT-should it be done?
Soloway MS; Arianayagam M
Urology; 2010 Oct; 76(4):794-6. PubMed ID: 20932403
[No Abstract] [Full Text] [Related]
8. BCG versus cytotoxic chemotherapy in the treatment of superficial bladder tumors.
Boccon-Gibod L
Prog Clin Biol Res; 1992; 378():55-7. PubMed ID: 1301586
[No Abstract] [Full Text] [Related]
9. Apparent failure of current intravesical chemotherapy prophylaxis to influence the long-term course of superficial transitional cell carcinoma of the bladder.
Lamm DL; Riggs DR; Traynelis CL; Nseyo UO
J Urol; 1995 May; 153(5):1444-50. PubMed ID: 7714962
[TBL] [Abstract][Full Text] [Related]
10. [Postoperative and adjuvant intravesical therapy of superficial bladder tumours. Clinical practice and applied therapeutic agents].
Lingnau A; Miller K; Steiner U; Jentzmik F; Weikert S; Schostak M
Aktuelle Urol; 2009 Sep; 40(5):307-9. PubMed ID: 19637135
[TBL] [Abstract][Full Text] [Related]
11. BCG in the management of superficial bladder cancer.
Guinan P; Richardson C; Hanna M; Rubenstein M
Prog Clin Biol Res; 1989; 303():447-53. PubMed ID: 2675002
[TBL] [Abstract][Full Text] [Related]
12. BCG-RIVM intravesical immunoprophylaxis for superficial bladder cancer.
Debruyne FM; van der Meijden AP; Schreinemachers LM; Geboers AD; Franssen MP; van Leeuwen MJ; Steerenberg PA; de Jong WH; Ruitenberg EJ
Prog Clin Biol Res; 1988; 269():511-24. PubMed ID: 3134662
[No Abstract] [Full Text] [Related]
13. [Treatment and follow-up of superficial bladder cancer].
Raitanen M
Duodecim; 2002; 118(9):903-9. PubMed ID: 12238168
[No Abstract] [Full Text] [Related]
14. When does superficial bladder cancer resist intravesical therapy?
Vögeli T; Ackermann R
Semin Urol; 1990 Nov; 8(4):248-53. PubMed ID: 2284531
[No Abstract] [Full Text] [Related]
15. Is intravesical chemotherapy for superficial bladder cancer still justified?
Okeke AA; Probert JL; Gillatt DA; Schwaibold H
BJU Int; 2005 Oct; 96(6):763-7. PubMed ID: 16153195
[No Abstract] [Full Text] [Related]
16. Intravesical and systemic chemotherapy of murine bladder cancer.
Soloway MS
Cancer Res; 1977 Aug; 37(8 Pt 2):2918-29. PubMed ID: 406041
[No Abstract] [Full Text] [Related]
17. Interview with Dr Richard Sylvester: transition cell carcinoma of the bladder. Interview by Christine McKillop.
Sylvester R
Eur Urol; 2007 Jun; 51(6):1748-50. PubMed ID: 17374436
[No Abstract] [Full Text] [Related]
18. New approaches to intravesical chemo-immunotherapy in superficial bladder cancer.
van der Meijden AP
Prog Clin Biol Res; 1992; 378():95-101. PubMed ID: 1301591
[No Abstract] [Full Text] [Related]
19. [Intravesical therapy: Influence on superficial bladder cancer recurrence].
García Rodríguez J; Fernández Gómez JM; Escaf Barmadah S; González Alvarez RC; Jalón Monzón A; Martínez Gómez FJ; Sánchez Trilla A; Regadera Sejas J
Arch Esp Urol; 2007; 60(1):36-43. PubMed ID: 17408170
[TBL] [Abstract][Full Text] [Related]
20. [International Consensus Panel--treatment strategies for superficial bladder cancer].
Adler S; St Niclas M
Aktuelle Urol; 2006 Sep; 37(5):320-3; discussion 322-3. PubMed ID: 17004179
[No Abstract] [Full Text] [Related]
[Next] [New Search]
